Right Molecule & Right Dose by Design: Model-Informed Target Candidate Profiling for an Optimised Bispecific First-in-Human
10:00 am - Thursday 9th July 2026
- Design from the clinic backwards. Translate the intended clinical outcome into a quantitative Target Candidate Profile, the receptor occupancy needed for efficacy, and therefore the affinity, valency and format your bispecific must be engineered to hit.
- Make the trade-offs visible early. Connect predicted human PK/PD, receptor occupancy and the efficacious dose to what is genuinely feasible to manufacture and administer, so the target exposure is achievable rather than aspirational, and bispecific-specific traps (e.g. TMDD, hook effect) are screened out up front.
- A faster, de-risked path to First-in-Human. Making these decisions together, and early, delivers a candidate and a starting dose optimised for both efficacy and feasibility, avoiding expensive late-stage redesign.
